KRYS
Price
$168.73
Change
+$2.93 (+1.77%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
4.89B
11 days until earnings call
MRUS
Price
$44.37
Change
+$2.54 (+6.07%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
3.06B
18 days until earnings call
Ad is loading...

KRYS vs MRUS

Header iconKRYS vs MRUS Comparison
Open Charts KRYS vs MRUSBanner chart's image
Krystal Biotech
Price$168.73
Change+$2.93 (+1.77%)
Volume$3.22K
Capitalization4.89B
Merus
Price$44.37
Change+$2.54 (+6.07%)
Volume$10.76K
Capitalization3.06B
KRYS vs MRUS Comparison Chart
Loading...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KRYS vs. MRUS commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KRYS is a StrongBuy and MRUS is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (KRYS: $165.80 vs. MRUS: $44.36)
Brand notoriety: KRYS and MRUS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KRYS: 73% vs. MRUS: 124%
Market capitalization -- KRYS: $4.88B vs. MRUS: $3.06B
KRYS [@Biotechnology] is valued at $4.88B. MRUS’s [@Biotechnology] market capitalization is $3.06B. The market cap for tickers in the [@Biotechnology] industry ranges from $266.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KRYS’s FA Score shows that 1 FA rating(s) are green whileMRUS’s FA Score has 1 green FA rating(s).

  • KRYS’s FA Score: 1 green, 4 red.
  • MRUS’s FA Score: 1 green, 4 red.
According to our system of comparison, MRUS is a better buy in the long-term than KRYS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KRYS’s TA Score shows that 6 TA indicator(s) are bullish while MRUS’s TA Score has 5 bullish TA indicator(s).

  • KRYS’s TA Score: 6 bullish, 4 bearish.
  • MRUS’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, KRYS is a better buy in the short-term than MRUS.

Price Growth

KRYS (@Biotechnology) experienced а +0.67% price change this week, while MRUS (@Biotechnology) price change was +3.03% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.94%. For the same industry, the average monthly price growth was -5.37%, and the average quarterly price growth was -12.15%.

Reported Earning Dates

KRYS is expected to report earnings on Aug 11, 2025.

MRUS is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+7.94% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KRYS($4.89B) has a higher market cap than MRUS($3.07B). KRYS YTD gains are higher at: 7.954 vs. MRUS (5.493). KRYS has higher annual earnings (EBITDA): 110M vs. MRUS (-269.6M). KRYS has more cash in the bank: 598M vs. MRUS (537M). KRYS has less debt than MRUS: KRYS (7.26M) vs MRUS (9.91M). KRYS has higher revenues than MRUS: KRYS (291M) vs MRUS (36.1M).
KRYSMRUSKRYS / MRUS
Capitalization4.89B3.07B159%
EBITDA110M-269.6M-41%
Gain YTD7.9545.493145%
P/E Ratio56.37N/A-
Revenue291M36.1M806%
Total Cash598M537M111%
Total Debt7.26M9.91M73%
FUNDAMENTALS RATINGS
KRYS vs MRUS: Fundamental Ratings
KRYS
MRUS
OUTLOOK RATING
1..100
64
VALUATION
overvalued / fair valued / undervalued
1..100
79
Overvalued
59
Fair valued
PROFIT vs RISK RATING
1..100
1832
SMR RATING
1..100
6792
PRICE GROWTH RATING
1..100
5457
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MRUS's Valuation (59) in the Biotechnology industry is in the same range as KRYS (79) in the Pharmaceuticals Major industry. This means that MRUS’s stock grew similarly to KRYS’s over the last 12 months.

KRYS's Profit vs Risk Rating (18) in the Pharmaceuticals Major industry is in the same range as MRUS (32) in the Biotechnology industry. This means that KRYS’s stock grew similarly to MRUS’s over the last 12 months.

KRYS's SMR Rating (67) in the Pharmaceuticals Major industry is in the same range as MRUS (92) in the Biotechnology industry. This means that KRYS’s stock grew similarly to MRUS’s over the last 12 months.

KRYS's Price Growth Rating (54) in the Pharmaceuticals Major industry is in the same range as MRUS (57) in the Biotechnology industry. This means that KRYS’s stock grew similarly to MRUS’s over the last 12 months.

KRYS's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as MRUS (100) in the Biotechnology industry. This means that KRYS’s stock grew similarly to MRUS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KRYSMRUS
RSI
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
81%
Momentum
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 10 days ago
76%
Bullish Trend 4 days ago
84%
Declines
ODDS (%)
Bearish Trend 17 days ago
76%
Bearish Trend 2 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
81%
Aroon
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
73%
View a ticker or compare two or three
Ad is loading...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RERCX54.010.63
+1.18%
American Funds Europacific Growth R3
LICQX15.65N/A
N/A
Lord Abbett International Equity R2
LMCCX27.56N/A
N/A
Lord Abbett Mid Cap Stock C
ABSAX18.79N/A
N/A
American Beacon Small Cp Val A
IENRX8.80N/A
N/A
Macquarie Climate Solutions R6

KRYS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KRYS has been loosely correlated with ACLX. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if KRYS jumps, then ACLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KRYS
1D Price
Change %
KRYS100%
+2.00%
ACLX - KRYS
55%
Loosely correlated
+0.53%
IDYA - KRYS
51%
Loosely correlated
+1.33%
CRNX - KRYS
50%
Loosely correlated
+3.15%
CGON - KRYS
49%
Loosely correlated
+3.81%
ROIV - KRYS
48%
Loosely correlated
+2.42%
More